Analyst Activity – Citigroup Inc. Reiterates Buy on PTC Therapeutics (NASDAQ:PTCT)

ME Staff
-
0

Analyst Ratings For PTC Therapeutics (NASDAQ:PTCT)

Today, Citigroup Inc. reiterated its Buy rating on PTC Therapeutics (NASDAQ:PTCT) with a price target of $17.00.

There are 7 hold ratings, 2 buy ratings on the stock.

The current consensus rating on PTC Therapeutics (NASDAQ:PTCT) is Hold (Score: 2.22) with a consensus target price of $15.25 per share, a potential 21.51% downside.

Some recent analyst ratings include

  • 7/20/2017-Citigroup Inc. Reiterated Rating of Buy.
  • 6/30/2017-J P Morgan Chase & Co Reiterated Rating of Neutral.
  • 3/22/2017-Barclays PLC Reiterated Rating of Equal Weight.
  • 3/16/2017-Cowen and Company Reiterated Rating of Hold.
  • 3/6/2017-Credit Suisse Group Reiterated Rating of Outperform .
  • 1/10/2017-Jefferies Group LLC Reiterated Rating of Hold.

Recent Insider Trading Activity For PTC Therapeutics (NASDAQ:PTCT)
PTC Therapeutics (NASDAQ:PTCT) has insider ownership of 8.10% and institutional ownership of 76.50%.

  • On 5/23/2017 Dawn Svoronos, Director, bought 25,000 with an average share price of $13.49 per share and the total transaction amounting to $337,250.00. View SEC Filing
  • On 1/5/2017 Neil Gregory Almstead, EVP, sold 78 with an average share price of $11.82 per share and the total transaction amounting to $921.96. View SEC Filing
  • On 3/3/2016 Mark Rothera, Insider, bought 2,000 with an average share price of $6.23 per share and the total transaction amounting to $12,460.00. View SEC Filing
  • On 7/6/2015 David P Southwell, Director, sold 23,604 with an average share price of $47.52 per share and the total transaction amounting to $1,121,662.08. View SEC Filing
  • On 6/18/2015 Allan Steven Jacobson, Director, sold 5,000 with an average share price of $50.13 per share and the total transaction amounting to $250,650.00. View SEC Filing
  • On 6/9/2015 Stuart Walter Peltz, CEO, sold 100,000 with an average share price of $54.49 per share and the total transaction amounting to $5,449,000.00. View SEC Filing
  • On 6/8/2015 Mark Elliott Boulding, VP, sold 56,849 with an average share price of $55.04 per share and the total transaction amounting to $3,128,968.96. View SEC Filing

Recent Trading Activity for PTC Therapeutics (NASDAQ:PTCT)
Shares of PTC Therapeutics closed the previous trading session at 20.57 up +1.14 5.87% with 450,741 shares trading hands.